Tenecteplase: More Evidence It Should Replace Alteplase for Ischemic Stroke Treatment - 20/11/23

| Supervising editor: William J. Meurer, MD. Specific detailed information about possible conflict of interest for individual editors is available at editors. |
|
| All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. |
|
| Funding and support: By Annals’ policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Kreitzer receives salary support from National Institute of Child and Human Development (NICHD) National Institute of Health (NIH), 5K23HD102555 and serves on the speaker bureau for AstraZeneca (Andexxanet Alfa). Dr. Kreitzer is also an unaffiliated neurotrauma consultant for the National Football League (NFL). |
|
| A podcast for this article is available at www.annemergmed.com. |
Vol 82 - N° 6
P. 729-731 - dicembre 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
